Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

14  Enrolling
26  Total Trials
Pinned
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)
Enrolling
Conditions: Obesity, Overweight, Osteoarthritis, Sleep Apnea
Trial Name
TRIUMPH-1
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4)
Enrolling
Conditions: Obesity, Overweight and Osteoarthritis of the Knee
Trial Name
TRIUMPH-4
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Enrolling
Conditions: Rheumatoid Arthritis
Drugs: LY3871801
Age
≥18 years
Phase
II
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Enrolling
Conditions: Systemic Juvenile Idiopathic Arthritis
Drugs: Baricitinib
Age
1 year - 17 years
Phase
III
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-1
Drugs: Lebrikizumab, Topical corticosteroid
Age
6 months - 17 years
Phase
III
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X)
Enrolling
Conditions: Juvenile Idiopathic Arthritis
Trial Name
JUVE-X
Drugs: Baricitinib
Age
1 year - 18 years
Phase
III
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Derm...
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADmirable
Drugs: Lebrikizumab
Age
≥12 years
Phase
III
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Enrolling
Conditions: Hidradenitis Suppurativa
Drugs: Eltrekibart
Age
18 - 75 years
Phase
II
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Drugs: Ucenprubart
Age
18 - 70 years
Phase
II
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
Enrolling
Conditions: Multiple sclerosis
Drugs: LY3541860
Age
18 - 55 years
Phase
II
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-...
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-2
Drugs: Lebrikizumab
Age
6 months - 18 years
Phase
III
A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)
Enrolling
Conditions: Rheumatoid Arthritis
Trial Name
RA-BRANCH
Drugs: Baricitinib, TNF Inhibitor
Age
≥18 years
Phase
IV
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)
Enrolling
Conditions: Alopecia Areata (hair loss)
Trial Name
BRAVE-AA-PEDS
Drugs: baricitinib
Age
6 - 17 years
Phase
III
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Enrolling
Conditions: Plaque Psoriasis
Drugs: LY3972406
Age
18 - 75 years
Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
3  Not Yet Enrolling
26  Total Trials
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
Not Yet Enrolling
Conditions: Atopic Dermatitis (Eczema)
Drugs: lebrikizumab, topical corticosteroid
Age
≥12 years
Phase
III
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Not Yet Enrolling
Conditions: Perennial Allergic Rhinitis (PAR)
Trial Name
PREPARED-1
Drugs: Lebrikizumab (LY3650150)
Age
≥18 years
Phase
III
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids...
Not Yet Enrolling
Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Drugs: Lebrikizumab (LY3650150)
Age
≥18 years
Phase
III
9 
Completed Enrollment
26  Total Trials
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (BRAVE-AA1)
Completed Enrollment
Conditions: Alopecia Areata (hair loss)
Trial Name
BRAVE-AA1
Drugs: Baricitinib
Age
18 - 70 years
Phase
III
A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
Completed Enrollment
Conditions: Aicardi Goutieres Syndrome (AGS)
Drugs: Baricitinib
Age
≥6 months
Phase
III
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS)
Completed Enrollment
Conditions: Atopic Dermatitis (Eczema)
Trial Name
BREEZE-AD-PEDS
Drugs: Baricitinib, Placebo
Age
2 - 17 years
Phase
III
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anteri...
Completed Enrollment
Conditions: Uveitis
Drugs: Baricitinib, Adalimumab
Age
2 - 17 years
Phase
III
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA-BRIDGE)
Completed Enrollment
Conditions: Rheumatoid Arthritis
Trial Name
RA-BRIDGE
Drugs: Baricitinib, TNF Inhibitor
Age
≥18 years
Phase
IV
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dup...
Completed Enrollment
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADapt
Drugs: Lebrikizumab
Age
≥12 years
Phase
III
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenil...
Completed Enrollment
Conditions: Arthritis
Drugs: Ixekizumab, Adalimumab
Age
2 - 17 years
Phase
III
A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (RESOLUTION-1)
Completed Enrollment
Conditions: Rheumatoid Arthritis
Trial Name
RESOLUTION-1
Drugs: Peresolimab
Age
≥18 years
Phase
II
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)
Completed Enrollment
Conditions: Alopecia Areata (Hair Loss)
Trial Name
BRAVE-AA2
Drugs: Baricitinib, Placebo
Age
18 - 70 years
Phase
III